Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...

The Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.

Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

PARIS, France I March 26, 2025 I The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention ...

US FDA grants fast track designation to Sanofi’s mRNA vaccine candidate for prevention of chlamydia infection: Paris Friday, March 28, 2025, 12:00 Hrs [IST] The US Food and Drug ...

The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.